Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
NCT04129320 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL
Last updated 2022-02-08
Summary
This is an open-label study designed to evaluate safety and efficacy of enoblituzumab in combination with MGA012 or MGD013 in first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Conditions
- Head and Neck Cancer
- Squamous Cell Carcinoma of Head and Neck
Interventions
- BIOLOGICAL
-
enoblituzumab
anti-B7-H3 antibody
- BIOLOGICAL
-
MGA012
anti-PD-1 antibody
- BIOLOGICAL
-
MGD013
PD-1 X LAG-3 bispecific DART protein
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-10-31
- Primary Completion
- 2020-10-31
- Completion
- 2022-10-31
- FDA Drug
- Yes
More Related Trials
-
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor
NCT04831320 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma
NCT06218004 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04428333 ·Status: TERMINATED ·Phase: PHASE3
-
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
NCT06046482 ·Status: TERMINATED ·Phase: PHASE2
-
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04128696 ·Status: TERMINATED ·Phase: PHASE3
-
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
NCT03468218 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
NCT06016413 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
NCT03386838 ·Status: WITHDRAWN ·Phase: PHASE3
-
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT01360827 ·Status: TERMINATED ·Phase: PHASE1
-
CD40 Agonist and PD-1 Inhibitor in HNSCC
NCT06159621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
NCT05068609 ·Status: COMPLETED
-
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
NCT03655444 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
NCT03342352 ·Status: WITHDRAWN ·Phase: PHASE3
-
Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N
NCT04323202 ·Status: COMPLETED ·Phase: PHASE1
-
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
NCT06308913 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
NCT04193293 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05287113 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas
NCT06557889 ·Status: RECRUITING ·Phase: PHASE2
-
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT00906360 ·Status: TERMINATED ·Phase: PHASE1
-
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
NCT04458909 ·Status: TERMINATED ·Phase: PHASE3
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
NCT02128906 ·Status: RECRUITING ·Phase: PHASE2
-
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
NCT01847326 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
NCT05783921 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
NCT03057613 ·Status: COMPLETED ·Phase: PHASE2